Palladia is the first FDA-approved anti-cancer medication developed specifically for dogs. Manufactured by Zoetis, Palladia contains toceranib phosphate, a receptor tyrosine kinase (RTK) inhibitor that targets multiple pathways involved in tumor growth and blood vessel formation. It was approved by the FDA in 2009 for the treatment of recurrent cutaneous mast cell tumors (Patnaik grade II or III) with or without regional lymph node involvement. Palladia is also used off-label for other canine cancers. It represents a significant advancement in veterinary oncology, offering an oral targeted therapy option for dogs with cancer.
What Is Palladia Used For?
Palladia is prescribed for cancer treatment in dogs:
- Recurrent cutaneous mast cell tumors (MCTs) — the FDA-approved indication; Patnaik grade II or III
- Other cancers (off-label) — various solid tumors, including anal sac adenocarcinoma, thyroid carcinoma, head and neck carcinomas, nasal tumors, and some sarcomas
- Metastatic disease — used in some cases to slow tumor progression
Palladia is typically prescribed by veterinary oncologists and requires regular monitoring. It is not a cure but can slow tumor growth, shrink tumors, and improve quality of life in many dogs with cancer.
How Does Palladia Work?
Toceranib is a multi-targeted receptor tyrosine kinase inhibitor. It works by blocking several key receptors involved in tumor growth:
- VEGFR-2 (vascular endothelial growth factor receptor): Inhibits the growth of new blood vessels that tumors need to grow (anti-angiogenesis)
- PDGFR-beta (platelet-derived growth factor receptor): Blocks signals that promote tumor cell proliferation
- Kit/SCFR (stem cell factor receptor): Particularly important for mast cell tumors, which often have activating mutations in the Kit receptor
By simultaneously targeting tumor blood supply and direct tumor cell growth signals, Palladia attacks cancer through multiple mechanisms. This multi-targeted approach is why it can be effective against several different cancer types.
Dosage
Palladia is prescribed and monitored by veterinarians, typically veterinary oncologists.
| Dog’s Weight | Approximate Dose | Schedule |
|---|---|---|
| Dosed by weight | 3.25 mg/kg | Every other day (Monday, Wednesday, Friday) |
- Standard dose: 3.25 mg/kg given on an every-other-day schedule (typically Monday, Wednesday, Friday)
- Available tablet strengths: 10 mg, 15 mg, 50 mg
- Dose reductions or treatment breaks may be necessary based on side effects and blood work results
- Your veterinary oncologist will determine the exact dose and adjust based on your dog’s response and tolerance
How to Give Palladia to Your Dog
- Give on an every-other-day basis as prescribed (commonly Monday, Wednesday, Friday).
- Can be given with or without food. Some oncologists recommend giving with food to reduce GI upset.
- Do not split or break tablets. Palladia tablets have a coating to prevent handler exposure.
- Wear disposable gloves when handling tablets. Toceranib can be absorbed through skin. Wash hands thoroughly after handling.
- Pregnant women should not handle Palladia tablets.
- If your dog vomits within 1 hour of dosing, do not re-dose — contact your veterinarian.
- Keep Palladia away from children and other animals.
Side Effects
Palladia has a significant side effect profile that requires careful monitoring.
| Common Side Effects | Serious Side Effects (Contact Your Vet) |
|---|---|
| Diarrhea (most common) | Severe or bloody diarrhea |
| Decreased appetite | Severe vomiting or dehydration |
| Vomiting | Neutropenia (low white blood cells — infection risk) |
| Weight loss | Thrombocytopenia (low platelets — bleeding risk) |
| Lethargy | Proteinuria (protein in urine — kidney damage) |
| Lameness or muscle pain | GI perforation or hemorrhage |
| Hypertension (high blood pressure) | |
| Hepatotoxicity (liver damage) |
Approximately 40-50% of dogs experience some degree of GI side effects. Serious adverse events are less common but require immediate veterinary attention. Regular monitoring (blood work and urinalysis every 2-3 weeks initially, then monthly) is essential.
Drug Interactions
- NSAIDs (carprofen, meloxicam): Increased risk of GI ulceration. Use with caution or avoid.
- Corticosteroids (prednisone): May increase GI side effects; however, the combination is sometimes used in oncology under close monitoring.
- Other chemotherapy agents: Additive bone marrow suppression. Combination protocols require oncologist supervision.
- CYP450 inhibitors and inducers: May affect toceranib blood levels.
Contraindications
- Known hypersensitivity to toceranib
- Dogs with severe GI disease or active GI bleeding
- Dogs with severe bone marrow suppression or low blood cell counts
- Pregnant, lactating, or breeding dogs
- Dogs with uncontrolled concurrent diseases that make monitoring difficult
Storage
- Store at controlled room temperature, 68-77degF (20-25degC).
- Keep in original child-resistant container.
- Keep away from children and pets — this is a cytotoxic agent.
- Do not store near food.
Cost & Availability
Palladia is a prescription veterinary oncology drug available only through veterinary clinics.
- Approximate cost: $300-$800+ per month depending on dog size and dose
- Available forms: Film-coated tablets (10 mg, 15 mg, 50 mg)
- No generic version is currently available
- Available through veterinary clinics and licensed veterinary pharmacies
- The cost of medication plus required monitoring (blood work, urinalysis) represents a significant financial commitment
Frequently Asked Questions
What is the success rate of Palladia for mast cell tumors? In clinical trials, approximately 37-42% of dogs with recurrent mast cell tumors showed objective tumor response (tumor shrinkage or stabilization). Some dogs experience significant tumor regression, while others achieve disease stabilization. Individual responses vary, and your veterinary oncologist can discuss expected outcomes based on your dog’s specific situation.
How long can a dog take Palladia? Treatment duration depends on the response and tolerance. Some dogs remain on Palladia for months to years if they tolerate it well and the cancer remains controlled. Treatment may be discontinued if side effects become unmanageable, the cancer progresses despite treatment, or the dog achieves and maintains remission.
Is Palladia chemotherapy? Palladia is a targeted cancer therapy rather than traditional cytotoxic chemotherapy. It targets specific receptors involved in tumor growth rather than killing all rapidly dividing cells indiscriminately. However, it still has significant side effects and requires the same level of veterinary monitoring as traditional chemotherapy.
Why do I need to wear gloves when handling Palladia? Toceranib is a potent kinase inhibitor that can be absorbed through human skin. Chronic exposure could theoretically have adverse health effects, particularly for pregnant women. The tablet coating helps minimize exposure, but gloves provide an additional safety margin.
Sources & References
- FDA - Palladia (Toceranib) Approval
- Zoetis - Palladia Product Information
- Merck Veterinary Manual - Cancer Chemotherapy
- Veterinary Cancer Society
- VCA Hospitals - Mast Cell Tumors in Dogs
Verification Notes
Palladia’s status as “the first FDA-approved cancer drug specifically for dogs (2009)” and its mechanism targeting “VEGFR-2, PDGFR-beta, Kit/SCFR” are confirmed by the research corpus. The description of significant GI and other side effects requiring monitoring is consistent with the research data. Pricing ($300-800+/month) aligns with the research corpus estimates.